Faldaprevir and Deleobuvir for HCV Genotype 1 Infection

In this phase 2b study, an interferon-free regimen consisting of the combination of a protease inhibitor (faldaprevir), a nonnucleoside polymerase inhibitor (deleobuvir), and ribavirin was effective for the treatment of chronic hepatitis C virus infection. The introduction of the direct-acting antiviral agents telaprevir and boceprevir (nonstructural protein 3/4A [NS3/4A] protease inhibitors) was a major advance in the management of chronic infection with hepatitis C virus (HCV) genotype 1, the most prevalent and difficult-to-cure genotype. 1 However, these drugs are used in combination with pegylated interferon alfa and ribavirin, which are associated with a high rate of side effects and discontinuation. 2 In addition, many patients cannot receive pegylated interferon because of contraindications. 3 Host genetic factors are known to influence the response to treatment with pegylated interferon and ribavirin in patients infected with HCV genotype 1. Single-nucleotide polymorphisms . . .